Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Drug Discovery & Development | Industry Spotlights & Insight Articles

Bispecific Antibody Format: Interview with Laura von Schantz, Chief Technology Officer, Alligator Biosciences

Edited by Tom Cohen | 02 November 2023
Talking with Laura von Schantz, Chief Technology Officer, at Alligator Biosciences about their RUBY bispecific antibody format.
https://www.youtube.com/watch?v=4OSaRG3A9g4&ab_channel=OxfordGlobal

More on antibody based therapies:

 

Also check out our flagship Immuno Conference: A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of cancer immunotherapies with dedicated sessions on different therapeutic modalities, biomarkers, precision and omics-based approaches in IO as well as case studies on innovative preclinical and translational tools.

Related Resources

FDA Grant Rare Pediatric Disease Designation to Omeros’s Antibody for C3 Glomerulopathy

Rare pediatric disease designation allows the company to access priority review from the FDA for a new drug application or biologics licence application.
Read More

Regeneron’s Bispecific Gets EU Approval After FDA Rejection

The approval means that the bispecific antibody odronextamab can be used to treat adult patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the EU.
Read More